NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing treatments for severe neurodegenerative diseases, announced on Monday that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled 'Compositions Comprising Ciprofloxacin and Celecoxib'.

The granted Brazilian patent, following prior approval of the corresponding US patent (12,097,185) and Australian patent (2022370513), provides protection for NeuroSense's proprietary PrimeC composition in Brazil and extends patent coverage until October 2042, further strengthening the company's global intellectual property estate and supporting the long-term development and potential commercialisation of PrimeC in ALS, Alzheimer's disease and additional neurodegenerative indications.

PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib in a synchronised, extended-release formulation specifically targeted to deliver both agents in a coordinated manner -- a key differentiator versus simple co-administration. The formulation is designed to enable consistent exposure across multiple disease pathways implicated in ALS, including neuroinflammation, iron dysregulation, and miRNA dysregulation, supporting a multi-target disease-modifying approach.

NeuroSense is preparing to start a Phase 3 pivotal clinical trial for PrimeC in ALS (PARAGON), following positive Phase 2b PARADIGM results and FDA clearance.